聚焦超声刺激微气泡增强放射治疗乳腺癌:一项1期临床试验
这项前瞻性单中心单臂1期临床试验纳入21例女性患者的23个乳腺肿瘤,在放疗期间接受2至3次磁共振引导聚焦超声刺激微气泡治疗。主要终点急性毒性以放射性皮炎最常见,3个月时18个可评估肿瘤中9个完全缓解,6、12、24个月局部控制率分别为94%、88%、76%。作者认为该疗法安全性良好、缓解 potentially 有前景且局部控制持久,结果需在2期试验中验证。
要点
- 21例女性患者的23个乳腺肿瘤入组,18例患者的20个肿瘤纳入安全性和局部控制分析。
- 放射性皮炎是最常见急性毒性,1级16/20、2级1/20、3级2/20。
- 6、12、24个月局部控制率分别为94%、88%、76%。
核心结论
- 作者认为磁共振引导聚焦超声刺激微气泡是一种创新的放射增强疗法,安全性良好、缓解 potentially 有前景且局部控制持久,结果需在2期临床试验中验证。
研究设计与样本
- 前瞻性、单中心、单臂1期临床试验,纳入21例女性患者的23个乳腺肿瘤,于2020年8月至2022年11月入组并分配至干预。
- 3例患者随后撤回知情同意,18例患者的20个肿瘤纳入安全性和局部控制分析;2例患者在治疗结束后3个月内因转移性疾病进展死亡,被排除于肿瘤缓解分析。
- 患者在整个放疗期间接受2至3次磁共振引导聚焦超声刺激微气泡治疗,使用工作频率800 kHz、峰值负压570 kPa的磁共振耦合聚焦超声装置对静脉注射的微气泡进行声波处理。
主要发现
- 处方放疗剂量为20 Gy/5次(40%,n=8/20)、30至35 Gy/5次(35%,n=7/20)、30至40 Gy/10次(15%,n=3/20)和66 Gy/33次(10%,n=2/20)。
- 中位随访9个月(范围0.3至29个月)。
- 放射性皮炎是最常见急性毒性,1级16/20、2级1/20、3级2/20;1例患者出现可能与应用微气泡相关的1级过敏反应。
- 3个月时18个肿瘤可评估缓解:完全缓解9个(50%,n=9/18)、部分缓解6个(33%,n=6/18)、疾病稳定2个(11%,n=2/18)、疾病进展1个(6%,n=1/18)。
- 6、12、24个月局部控制率分别为94%(95%CI[84%,100%])、88%(95%CI[75%,100%])和76%(95%CI[54%,100%])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 肿瘤大小和剂量分割方案存在差异。
- 样本量小,为1期临床试验的预期特征。
- 作者指出结果需在2期临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical studies have demonstrated that tumour cell death can be enhanced 10- to 40-fold when radiotherapy is combined with focussed ultrasound-stimulated microbubble (FUS-MB) treatment. The acoustic exposure of microbubbles (intravascular gas microspheres) within the target volume causes bubble cavitation, which induces perturbation of tumour vasculature and activates endothelial cell apoptotic pathways responsible for the ablative effect of stereotactic body radiotherapy. Subsequent irradiation of a microbubble-sensitised tumour causes rapid increased tumour death. The study here presents the mature safety and efficacy outcomes of magnetic resonance (MR)-guided FUS-MB (MRgFUS-MB) treatment, a radioenhancement therapy for breast cancer. METHODS AND FINDINGS: This prospective, single-center, single-arm Phase 1 clinical trial included patients with stages I-IV breast cancer with in situ tumours for whom breast or chest wall radiotherapy was deemed adequate by a multidisciplinary team (clinicaltrials.gov identifier: NCT04431674). Patients were excluded if they had contraindications for contrast-enhanced MR or microbubble administration. Patients underwent 2 to 3 MRgFUS-MB treatments throughout radiotherapy. An MR-coupled focussed ultrasound device operating at 800 kHz and 570 kPa peak negative pressure was used to sonicate intravenously administrated microbubbles within the MR-guided target volume. The primary outcome was acute toxicity per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Secondary outcomes were tumour response at 3 months and local control (LC). A total of 21 female patients presenting with 23 primary breast tumours were enrolled and allocated to intervention between August/2020 and November/2022. Three patients subsequently withdrew consent and, therefore, 18 patients with 20 tumours were included in the safety and LC analyses. Two patients died due to progressive metastatic disease before 3 months following treatment completion and were excluded from the tumour response analysis. The prescribed radiation doses were 20 Gy/5 fractions (40%, n = 8/20), 30 to 35 Gy/5 fractions (35%, n = 7/20), 30 to 40 Gy/10 fractions (15%, n = 3/20), and 66 Gy/33 fractions (10%, n = 2/20). The median follow-up was 9 months (range, 0.3 to 29). Radiation dermatitis was the most common acute toxicity (Grade 1 in 16/20, Grade 2 in 1/20, and Grade 3 in 2/20). One patient developed grade 1 allergic reaction possibly related to microbubbles administration. At 3 months, 18 tumours were evaluated for response: 9 exhibited complete response (50%, n = 9/18), 6 partial response (33%, n = 6/18), 2 stable disease (11%, n = 2/18), and 1 progressive disease (6%, n = 1/18). Further follow-up of responses indicated that the 6-, 12-, and 24-month LC rates were 94% (95% confidence interval [CI] [84%, 100%]), 88% (95% CI [75%, 100%]), and 76% (95% CI [54%, 100%]), respectively. The study's limitations include variable tumour sizes and dose fractionation regimens and the anticipated small sample size typical for a Phase 1 clinical trial. CONCLUSIONS: MRgFUS-MB is an innovative radioenhancement therapy associated with a safe profile, potentially promising responses, and durable LC. These results warrant validation in Phase 2 clinical trials. TRIAL REGISTRATION: clinicaltrials.gov, identifier NCT04431674.
引用
- Moore-Palhares D, Dasgupta A, Saifuddin M, et al. Radiation enhancement using focussed ultrasound-stimulated microbubbles for breast cancer: A Phase 1 clinical trial. PLoS Med. 2024. PMID: 38758967. doi:10.1371/journal.pmed.1004408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。